Morning Overview on MSN
Why cancer returns years later, and how we can stop it
Cancer’s cruelest trick is its ability to disappear, only to reappear years later in a new organ or a familiar scar. The fear ...
-- Proceeds to drive global Phase 3 trial for ASP-1929, targeting BLA submission to the U.S. FDA in 2028 -- Financing led by international life science fund TaiAx, with participation from the largest ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...
They plan to run similar trials on seven more patients over the next three years, backed by $4 million from the National ...
Morning Overview on MSN
1 protein block slowed cancer in mice, and it’s a promising target
Researchers have identified a single protein whose absence can cripple tumors in mice, slowing their growth and in some cases ...
Optune Lua adoption lag hit shares, but 2026 catalysts and $230M net cash could drive a rebound. Know more about NVCR stock ...
After eight years of training, Dr. Maureen McKiernan made her debut as the lead surgeon on an infant heart transplant — an ...
Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
Iovance Biotherapeutics targets significant market expansion, with lung cancer representing a $10B U.S. peak sales ...
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Looking for work? Find jobs with help from Indeed & AARP that ...
A groundbreaking lung cancer vaccine will be tested on humans from summer 2026, with British scientists working on jabs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback